← Research
Research documentationModel card · v0.1 · November 2026

NeuroFusion-AD

Model card for NFAD, a multimodal graph neural network researched for amyloid-positivity and cognitive-decline risk in mild cognitive impairment. Not approved or available for clinical use.

01  Model details

Graph neural network with multimodal fusion. Each patient is represented as a heterogeneous graph in which biomarker, speech, gait and demographic nodes are joined by learned weighted edges, so that relationships between modalities are modelled directly. Developed by AlgoMD, Pune.

02  Intended use (draft)

Non-autonomous clinical decision support for adults with mild cognitive impairment, estimating risk to inform a clinician’s decision on specialist referral. Design target: EU MDR Class IIa SaMD.

Out of scope:diagnosing Alzheimer’s disease; use without clinician oversight; use in people without MCI; use in populations not represented in the evaluation data.

03  Inputs

  • Plasma biomarkers: pTau181 and NfL.
  • Speech: 60-second Cookie Theft picture description, acoustic and linguistic features.
  • Gait: 30-second smartphone accelerometry, spatiotemporal features.
  • Demographics: age, sex, APOE4 genotype, MMSE score.

04  Data

Developed and evaluated on ADNI, with a second held-out evaluation on Bio-Hermes-001. Final validation on DementiaBank is planned; access requires company incorporation and is on hold.

05  Retrospective research results

MetricADNI test setBio-Hermes-001 test set
Amyloid positivity AUC0.88970.9071
Cognitive decline RMSE1.804 pts/yr—
Dementia progression C-index0.651—

Results from held-out splits of research datasets. They are not clinical performance claims and do not show that NFAD is accurate in clinical practice or in any population outside these cohorts.

06  Limitations

  • Data leakage was found during development and corrected by reducing model capacity and rebuilding the train–test split protocol. Earlier, higher figures are superseded.
  • ADNI and Bio-Hermes-001 may not represent Indian or other under-studied populations. No evaluation on Indian patients has been done.
  • No prospective evaluation has been done.
  • The dementia progression C-index of 0.651 indicates limited discrimination for that task.

07  Version & contact

Version 0.1, November 2026. Questions or corrections: regulatory@algo-md.com.